Notice of ceasing to be a substantial holder

Feb 14, 2020
Posted in: Investor updates

Home » Notice of ceasing to be a substantial holder

Notice of ceasing to be a substantial holder

Feb 14, 2020
Posted in: Investor updates

Form 605, “Notice of ceasing to be a substantial holder”, has been released to the ASX.

The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging

October 17, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

September 4, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice of ceasing to be a substantial holder

Notice of ceasing to be a substantial holder

Related Articles

The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list